Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have received an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.25.

ESPR has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Piper Sandler assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 target price for the company. Needham & Company LLC lifted their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd.

More Esperion Therapeutics News

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Q4 revenue beat — Esperion reported a 144% jump in Q4 revenue to $168.4M, comfortably beating consensus and showing strong top-line growth that supports the company’s commercial traction. ESPR’s Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
• Neutral Sentiment: HC Wainwright retains a Buy rating and provided detailed quarterly estimates for 2026 (Q1: -$0.08, Q2: -$0.05, Q3: -$0.04, Q4: $0.05) — the firm expects the company to reach roughly break-even in FY2026. This keeps upside narrative alive, but the path is mixed near-term. MarketBeat ESPR
• Negative Sentiment: Material downward revisions to longer-term EPS — HC Wainwright cut FY2026 EPS to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). Those reductions lower investor expectations for multi-year profitability and likely explain downward pressure on the stock despite the revenue beat. MarketBeat ESPR

Esperion Therapeutics Stock Down 4.6%

Shares of NASDAQ ESPR opened at $2.47 on Friday. The business’s 50 day moving average price is $3.30 and its two-hundred day moving average price is $3.14. The company has a market cap of $590.48 million, a PE ratio of -14.53, a price-to-earnings-growth ratio of 1.47 and a beta of 1.11. Esperion Therapeutics has a twelve month low of $0.69 and a twelve month high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $168.45 million during the quarter, compared to the consensus estimate of $165.12 million. As a group, research analysts anticipate that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Insider Activity at Esperion Therapeutics

In other news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total transaction of $26,926.79. Following the transaction, the chief financial officer owned 467,525 shares in the company, valued at approximately $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 15,543 shares of company stock valued at $55,709 over the last 90 days. 1.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ESPR. AIGH Capital Management LLC bought a new position in Esperion Therapeutics during the third quarter worth about $7,950,000. Two Seas Capital LP boosted its holdings in Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after purchasing an additional 3,024,104 shares during the period. Royce & Associates LP acquired a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $6,078,000. Diametric Capital LP grew its position in shares of Esperion Therapeutics by 57.8% during the 2nd quarter. Diametric Capital LP now owns 678,824 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 248,648 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Esperion Therapeutics during the third quarter worth approximately $476,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.